Le Lézard
Classified in: Health
Subjects: PDT, TDS

Biologica Technologies® showcases AMP aesthetictm at Plastic Surgery The Meeting 2017



CARLSBAD, Calif., Oct. 6, 2017 /PRNewswire/ -- Biologica Technologies, developers and marketers of Allofill®, announced today that they will be introducing AMP aesthetic at the upcoming Plastic Surgery The Meeting, the annual conference hosted by the American Society of Plastic Surgeons (ASPS).

AMP aesthetic is the first product of its kind, an allogeneic-derived growth factor that can be used in the same manner as platelet rich plasma (PRP). The product contains a full cascade of growth factors, including but not limited to; PDGF, TGF-?1, and VEGF. In comparison with market leading PRP systems and the PRP processed, AMP aesthetic possesses sufficiently higher growth factor amounts. Additionally, when AMP aesthetic is combined with autologous fat transfer (AFT), early data has exhibited higher graft retention than AFT alone.

"AMP aesthetic continues our company's commitment of bringing cutting edge tissue-based technologies to the field of aesthetics," stated Scott Cadotte, Vice President of Sales & Marketing of Biologica Technologies. "It provides a cost-effective 'off the shelf' option for plastic surgeons and their patients."

About Biologica Technologies
Founded in 2015, Biologica Technologies is a privately-held company fully dedicated to improving patients' lives and the health care providers' experience through innovative biologic solutions. Their first aesthetic product, Allofill, is an adipose-derived filler containing naturally occurring growth factors that can be used to fill soft-tissue defects as a noninvasive alternative to autologous fat grafting. The company is headquartered in Carlsbad, CA.

Related Links
www.biologicatechnologies.com
www.allofill.com

 

SOURCE Biologica Technologies


These press releases may also interest you

15 déc 2017
ESSA Pharma Inc. ("ESSA" or the "Company") announces an update to its previously announced pricing press release. The Company intends to issue up to 75,000,000 units of the Company ("Units") at a price of US$0.20 per Unit (the "Offering Price") for...

15 déc 2017
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Endologix, Inc. .   On August 2, 2016,...

15 déc 2017
The food recall warning issued on December 9, 2017 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. Imperial Caviar...

15 déc 2017
Valeant Pharmaceuticals International, Inc. ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the...

15 déc 2017
Recognizing that Centene Corporation's Washington subsidiary, Coordinated Care, has been in active discussions with the State of Washington Office of the Commissioner (OIC) for some time, today Coordinated Care finalized the terms of an agreement...

15 déc 2017
Aurora Cannabis Inc. ("Aurora") today announced that the Company has granted a total of 850,000 options to certain employees and directors of the Company, exercisable at $7.00 per common share. The options shall vest quarterly over a period of 36...




News published on 6 october 2017 at 07:45 and distributed by: